Preventive treatment can reverse cognitive impairment in chronic migraine

Autor: Cristina González-Mingot, Anna Gil-Sánchez, Marc Canudes-Solans, Silvia Peralta-Moncusi, Maria José Solana-Moga, Luis Brieva-Ruiz

Publikováno v: The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-12 (2022)

Abstract Objective To study the impact of chronic migraine (CM) on the cognition and quality of life (QoL) of patients in the interictal period, and to analyse the degree of reversibility of any observed alterations following the use of preventive tr

Externí odkaz: https://doaj.org/article/8a673fccabe74456a442df512b06ae91

Preventive treatment modifies endothelial function and oxidative stress status in patients with migraine: an observational study

Autor: Cristina González Mingot, Sonia Santos Lasaosa, Laura Colàs Campàs, Laura Chilangua Canaval, Anna Gil Sánchez, Luis Brieva Ruiz, María Cristina Marzo Alonso, Silvia Peralta Moncusí, Joan Valls Marsal, Serafí Cambray Carner, Francisco Purroy García

Background To evaluate whether preventive treatment can modify endothelial function and the oxidative stress profile of patients with migraines. Methods 88 treatment-naïve patients with migraines and 56 healthy sex/age matched controls underwent ult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b2dea7e357392134f8068d02d91df7c5
https://doi.org/10.21203/rs.3.rs-2506047/v1

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Autor: John F Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A Cohen, Douglas L Arnold, Helmut Butzkueven, Gary Cutter, Gavin Giovannoni, Joep Killestein, Heinz Wiendl, Karen Smirnakis, Shan Xiao, George Kong, Robert Kuhelj, Nolan Campbell, Anneke van der Walt, Christopher Dwyer, Katherine Buzzard, Judith Spies, John Parratt, Vincent van Pesch, Barbara Willekens, Gaetano Perrotta, Emmanuel Bartholomé, Francois Grand'Maison, Francois Jacques, Paul Giacomini, Reza Vosoughi, Jean-Marc Girard, Jerome de Seze, Christine Lebrun Frenay, Aurelie Ruet, David-Axel Laplaud, Gerd Reifschneider, Bert Wagner, Sebastian Rauer, Refik Pul, Maria Seipelt, Achim Berthele, Luisa Klotz, Boris-Alexander Kallmann, Friedemann Paul, Anat Achiron, Giacomo Lus, Diego Centonze, Francesco Patti, Luigi Grimaldi, Raymond Hupperts, Stephan Frequin, Jiske Fermont, Sara Eichau Madueno, Ana Maria Alonso Torres, Lucienne Costa-Frossard França, Jose Eustasio Meca-Lallana, Luis Brieva Ruiz, Owen Pearson, David Rog, Nikolaos Evangelou, Azza Ismail, Ellen Lathi, Edward Fox, Thomas Leist, Jacob Sloane, Gregory Wu, Bhupendra Khatri, Brian Steingo, Ben Thrower, Mark Gudesblatt, Jonathan Calkwood, Daniel Bandari, John Scagnelli, Christopher Laganke, Derrick Robertson, Lucas Kipp, Martin Belkin, Stanley Cohan, Lawrence Goldstick, Ardith Courtney, Wendy Vargas, Andrew Sylvester, Jayshri Srinivasan, Meena Kannan, Maryann Picone, Jeffrey English, Salvatore Napoli, Roumen Balabanov, Islam Zaydan, Jacqueline Nicholas, Jeffrey Kaplan, Fred Lublin, Emily Riser, Tamara Miller, Enrique Alvarez, Sibyl Wray, Jeffrey Gross, Siddharama Pawate, Carrie Hersh, Lucas McCarthy, Heidi Crayton, Jennifer Graves

Publikováno v: Foley, J F, Defer, G, Ryerson, L Z, Cohen, J A, Arnold, D L, Butzkueven, H, Cutter, G, Giovannoni, G, Killestein, J, Wiendl, H, Smirnakis, K, Xiao, S, Kong, G, NOVA study investigators, Kuhelj, R & Campbell, N 2022, ' Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA) : a randomised, controlled, open-label, phase 3b trial ', Lancet Neurology, vol. 21, no. 7, pp. 608-619 . https://doi.org/10.1016/S1474-4422(22)00143-0
The lancet neurology
Lancet Neurology, 21(7), 608-619. Lancet Publishing Group

Background: Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy. Switching to extended-interval dosing is asso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f21f3144ffc325fc4897a835c552966d
https://hdl.handle.net/20.500.11769/548322

A study to evaluate the effect of ultrasound treatment on nodules in multiple sclerosis patients

Autor: Luis Brieva Ruiz, Lourdes Assens Tauste, Blanca Guiu Badia, Eugenia Lacasa Andrade, Joan Valls Marsal, Silvia Peralta Moncusí, Marta Lordan Pujol, Anna Gil Sánchez, Lara Nogueras Peñabad, Jorge Lecina Monge, Cristina González Mingot, Albert Sacristán Argemí, Margarita Casalilla Puértolas, Nuria Sáez Calero, Mónica Nieves i Collado, Hugo Gonzalo Benito

Publikováno v: International Journal of Neuroscience. 127:404-411

Purpose/aim: Ultrasound has demonstrated anti-inflammatory and pain-relief benefits in several conditions such as cellulite or trauma events. We assessed the efficacy of ultrasound therapy on nodules associated with first-line treatments in multiple

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd6397e8ba1ab25b6a442f5ef8809dfe
https://doi.org/10.1080/00207454.2016.1186025

Adherence to Disease-Modifying Therapies in Spanish Patients with Relapsing Multiple Sclerosis: Two-Year Interim Results of the Global Adherence Project

Autor: Cai Grau, Luis Brieva Ruiz, Francisco LACRUZ, Cristina Ramo-Tello, Eduardo Aguera-Morales, Jaume Roquer Gonzalez

Publikováno v: European Neurology. 65:59-67

The post-marketing international Global Adherence Project investigated adherence to disease-modifying therapy for relapsing-remitting multiple sclerosis. We report adherence data from the first 2 years in the Spanish subset of patients (n = 254 at ba

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d815ae008f2daeeb3181ab048459dc0d
https://doi.org/10.1159/000323216